A Phase II, Randomized, Double-Blind, Placebo-Controlled Pilot Study of the Safety, Tolerability and Activity of Intramuscularly Administered a-Epi-Br (HE2000) in Late Stage Human Immunodeficiency Virus-Infected Patients at Risk for Opportunistic Infections
Latest Information Update: 24 Oct 2009
At a glance
- Drugs HE 2000 (Primary)
- Indications HIV infections
- Focus Adverse reactions
- Sponsors Harbor Therapeutics
- 04 Oct 2006 New trial record.